Table 2.
Characteristics of vaccines and vaccination programs used in the economic evaluations of pertussis vaccination for adolescents and adults.
| Study | Vaccine coverage | Vaccine efficacy /effectiveness | Adverse events following immunization | Duration of protection / Waning Immunity | Herd protection |
|---|---|---|---|---|---|
| Edmunds et al.14 | 84% | 95% | NC | 5 years | Yes |
| Scuffham e McIntyre15 | 95% (adults) | Adults 75%; At birth 67%; 1-month 75% | NC | NC | No |
| Purdy et al.16 | 40% (adolescents and adults) | 88% | 1% | 10 years | No |
| Iskedjian et al.17 | 95% | 85% | NC | NC | No |
| Caro et al.18 | 80% | 85% | 2% | 10 years | Yes |
| Iskedjian et al.19 | 85% | 85% | NC | NC | Not |
| Lee et al.20 | Coverage by age: 10 years 76%; 20 years 36%; 30 years 34%; 40 years 29%; 50 years 21%; 60 years 14%; 70 years 5%; postpartum 66% | 100% | Local reaction 2%; Systemic reaction 1%; Anaphylaxis 0.0001% | 15 years | Yes |
| Calugar et al.21 | 66% | 71.4% | Anaphylaxis 0.0001% | 10 years | No |
| Lee et al.22 | 20–49 years of age: 66%; 50–64 years of age: 57% | 87% | Local reactions: 2%; Systemic reactions: 1%; Anaphylaxis: 0,0001% |
15 years | Yes |
| Lee et al.23 | Coverage by age: 20 years 82%; 30 years 58%; 40 years 40%; 50 years 75%; 60 years 62% | 87% | Local reactions 2%. Systemic reactions 1%. Anaphylaxis 0,0001% |
15 years | Yes |
| Coudeville et al.24 | Adolescents 75%; adults 40%; cocooning 65% | 92% | Additional medical consultations for AEFI (2%) in vaccination cost | 12 years | Yes |
| Westra et al.25 | 96% | 89% | NC | 4 months (persistence of maternal antibodies in infants) | No |
| de Vries et al.26 | 96% | 89% | NC | Two scenarios: 8 and 15 years | Yes |
| Greer and Fisman27 | 25 to 95% | 100% | Anaphylaxis 0.00001% | NC | No |
| Rozenbaum et al.28 | 70% | 89% | NC | 10 years | Yes |
| Itatani et al.29 | 11–12 years of age 70%; >12 years 20% |
85% | Severe (anaphylaxis) 0.0001%; moderate 2% | 10 years | No |
| Meregaglia et al.30 | NR | 89% | NC | NC | No |
| Ding et al.31 | 25 to 60% | 80% | Local reaction 2%; Systemic reaction 1%; Anaphylaxis 0.0001% |
10 years | No |
| Terranella et al.32 | 72% | Adults vaccination: 85%; Efficacy of maternal vaccination on newborn protection 60% | NC | 2 months (persistence of maternal antibodies in infants) | No |
| Lugnér et al.33 | 75% | 89% | NC | 5 years | No |
| McGarry et al.34 | 10% | 89% | Included in the vaccine cost | 8 years | No |
| McGarry et al.35 | 10% (at 65 years of age) | 89% | Included in the vaccine cost | 8 years | Yes |
| Fernández-Canoa et al.36 | 50%, 80% and 100% | Adults vaccination: 85% Efficacy of maternal vaccination on newborn protection 60% |
NC | 2 months (persistence of maternal antibodies in infants) | No |
| Kamiya et al.37 | Coverage by age: 11 years 78%; 16 years 50%; 21 years 64% | 74% | Medically-attended allergic reactions 0.003%; Anaphylaxis 0.00006% |
15% decrease of vaccine effectiveness each year post-vaccination | No |
| Atkins et al.38 | 75% | Adults vaccination: 100%; Maternal vaccination on newborn protection 89% |
US$0.93 added to vaccination cost | 2.7 years | Yes |
| Sartori et al.39 | 57% | 78% | NC | 6 months (duration of maternal antibody protection); 4 months in SA | No |
| Hoek et al.40 | 60% | Infants 91%; Mother 89% |
NC | 3 months (persistence of maternal antibodies); 5 years among adults |
No |
NC – Not Considered; NR – not reported: SA – Sensitivity analyses; AEFI - adverse event following vaccination